A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

BACKGROUND: Anti-angiogenic treatment is believed to have at least cystostatic effects in highly vascularized tumours like pancreatic cancer. In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and gemcitabine were compared with gemcitabine alone in patients with advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Friess, Helmut, Langrehr, Jan M, Oettle, Helmut, Raedle, Jochen, Niedergethmann, Marco, Dittrich, Christian, Hossfeld, Dieter K, Stöger, Herbert, Neyns, Bart, Herzog, Peter, Piedbois, Pascal, Dobrowolski, Frank, Scheithauer, Werner, Hawkins, Robert, Katz, Frieder, Balcke, Peter, Vermorken, Jan, van Belle, Simon, Davidson, Neville, Esteve, Albert Abad, Castellano, Daniel, Kleeff, Jörg, Tempia-Caliera, Adrien A, Kovar, Andreas, Nippgen, Johannes
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1764757/
https://www.ncbi.nlm.nih.gov/pubmed/17156477
http://dx.doi.org/10.1186/1471-2407-6-285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1764757/
https://www.ncbi.nlm.nih.gov/pubmed/17156477
http://dx.doi.org/10.1186/1471-2407-6-285

Ejemplares similares